Clinical trial
A Preliminary Study to Evaluate the Safety and Efficacy of LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement
NCT07733076 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Preliminary Study to Evaluate the Safety and Efficacy of LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- September 30, 2028
- Enrollment
- 15 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.